Orexin Neurocircuit & Pharmacology Explorer v2.4 Live Model

Hypothalamic Flip-Flop Circuit

Consolidated Wake
Orexin Tone (LH) 85 Hz
VLPO Sleep Drive 22%
Monoaminergic Output 90%
Flip-Flop Stability 0.94
85%
20%
80%
15%
Mechanistic Note: Orexin peptides (Hypocretin-1 & 2) act as an indispensable non-reciprocal stabilizer, driving monoaminergic nuclei (LC, TMN, DR) to prevent sudden, inappropriate state transitions into REM/NREM sleep.

Receptor Binding & Pharmacology Console

Endogenous Orexin-A
Select Ligand / Modulator
50 nM
1.0x (Equipotent)

OX1R (Hcrtr1)

82% Occupied
Affinity Ki: 2.4 nM
Signaling Pathway: Gq/11 → PLCβ → IP3/Ca²⁺
Primary Phenotype: Addiction, Stress, Panic

OX2R (Hcrtr2)

82% Occupied
Affinity Ki: 2.5 nM
Signaling Pathway: Gq/11 + Gi/o → Depol
Primary Phenotype: Arousal & REM Suppression
Pharmacodynamic Insight: While Dual Orexin Receptor Antagonists (DORAs) promote physiological sleep architecture without GABAergic hangover or motor ataxia, selective OX2R agonists directly replace missing hypocretinergic tone to abolish cataplexy.

Therapeutic Translation & Clinical Indication Matrix